Error loading player: No playable sources found
2060
AASLD Presidential Plenary
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AASLD
Presentations:
| ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) |
| EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS |
| ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) |
| EFFECT OF EMPAGLIFLOZIN ON LIVER FAT IN METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITHOUT DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL |
| PROJECTED PREVALENCE OF CIRRHOSIS AND OVERT HEPATIC ENCEPHALOPATHY IN THE UNITED STATES, 2021–2030 |
| EVALUATING THE IMPACT OF CO-EXISTING INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A LARGE COHORT RETROSPECTIVE STUDY |
Moderators
Stanford University
Duke University
Speakers
Related Products
AASLD Basic Science Emerging Topic Conference Day 2 $$$
SOCIETY: AASLD Please note that this session requires an additional registration fee to attend…
Practice Guidelines (AASLD)
ACUTE ON CHRONIC LIVER FAILURE AND THE MANAGEMENT OF CRITICALLY ILL PATIENTS WITH CIRRHOSIS + Q&A
AASLD Basic Science Emerging Topic Conference Day 1 $$$
SOCIETY: AASLD Join AASLD for an enlightening session where experts delve into groundbreaking research at the intersection of microbiome science and liver health…
